Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria

American Journal of Nephrology

Volumn 29, Issue 2, 2009, Pages 86-93

  Grujic, Danica ^a   Salido, Eduardo C ^b   Shenoy, Bhami C ^a   Langman, Craig B ^c   McGrath, Margaret E ^a   Patel, Reena J ^a   Rashid, Aftab ^a   Mandapati, Saraswathi ^a   Jung, Chu W ^a   Margolin, Alexey L ^a  

^a Altus Pharmaceuticals Inc   (United States)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bladder stones; Hyperoxaluria, mouse model; Nephrocalcinosis; Oral therapy; Oxalate degrading enzyme

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; ETHYLENE GLYCOL; OXALATE DECARBOXYLASE; OXALIC ACID DERIVATIVE; OXDC CLEC; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FOOD; HYPEROXALURIA; KIDNEY CALCIFICATION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; URINALYSIS; UROLITHIASIS;

ADMINISTRATION, ORAL; AMINO ACID TRANSPORT SYSTEMS; ANIMALS; CARBOXY-LYASES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; ETHYLENE GLYCOL; FECES; HYPEROXALURIA; KIDNEY; MALE; MICE; MICE, KNOCKOUT; NEPHROCALCINOSIS; OXALATES; PEPTIDE HYDROLASES; UROLITHIASIS;

EID: 49049106988     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151395     Document Type: Article

References (27)

1. Bobrowski AE, Langman CB: Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother 2006;7:1887-1896.
2. Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB: Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999;56:268-274.
3. Milliner D: Treatment of the primary hyperoxalurias: a new chapter. Kidney Int 2006;70:1198-1200.
4. Costello JF, Smith M, Stolarski C, Sadovnic MJ: Extrarenal clearance of oxalate increases with the progression of renal failure in the rat. J Am Soc Nephrol 1992;3:1098-1104.
5. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW: Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69:691-698.
6. Goldfarb DS, Modersitziki F, Asplin JR: A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2007;2:745-749.
7. Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H: Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006;70:1305-1311.
8. Roy-Chowdhury J, Roy-Chowdhury N, Lu Y, Wang X, Thummala NR, Guha C, Santana A, Shapiro LJ, Saliodo E: Generation and characterization of a novel mouse model of primary hyperoxaluria-1 by disruption of the alanine: glyoxylate aminotransferase-1 gene: amelioration of hyperoxaluria by adenovector-mediated gene therapy. Hepatology 2004;40:254A.
9. Guha C, Yamanouchi K, Jiang J, Wang X, Roy-Chowdhury N, Santana A, Shapiro LJ, Saliodo E, Roy-Chowdhury J: Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. Am J Nephrol 2005;25:161-170.
10. Salido EC, Li XM, Lu Y, Wang X, Santana A, Roy-Chowdhury N, Torres A, Shapiro LJ, Roy-Chowdhury J: Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci USA 2006;103:18249-18255.
11. Just VJ, Stevenson CE, Bowater L, Tanner A, Lawson DM, Bornemann S: A closed conformation of Bacillus subtilis oxalate decarboxylase OxdC provides evidence for the true identity of the active site. J Biol Chem 2004;279:19867-19874.
12. Margolin AL, Navia MA: Protein crystals as novel catalytic materials. Angew Chem Int Ed Engl 2001;40:2204-2222.
13. Basu SK, Govardhan CP, Jung CW, Margolin AL: Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther 2004;4:310-317.
14. Tanner A, Bowater L, Fairhurst SA, Bornemann S: Oxalate decarboxylase requires manganese and dioxygen for activity. Overexpression and characterization of Bacillus subtilis YvrK and YoaN. J Biol Chem 2001;276:43627-43634.
15. Anand R, Dorrestein PC, Kinsland C, Begley TP, Ealick SE: Structure of oxalate decarboxylase from Bacillus subtilis at 1.75 A resolution. Biochemistry 2002;41:7659-7669.
16. Green ML, Hatch M, Freel RW: Ethylene glycol induces hyperoxaluria without metabolic acidosis in rats. Am J Physiol Renal Physiol 2005;289:F536-F543.
17. Holmes RP, Kennedy M: Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int 2000;57:1662-1667.
18. Yasue T: Histological identification of calcium oxalate. Acta Histochem Cytochem 1969;2:83-95.
19. Hatch M: Oxalate status in stone-formers. Two distinct hyperoxaluric entities. Urol Res 1993;21:55-59.
20. Hatch M, Freel RW: Intestinal transport of an obdurate anion: oxalate. Urol Res 2005;33:1-16.
21. Leumann E, Hoppe B: The primary hyperoxalurias. J Am Soc Nephrol 2001;12:1986-1993.
22. Holmes RP, Goodman HO, Assimos DG: Dietary oxalate and its intestinal absorption. Scanning Microsc 1995;9:1109-1120.
23. Meneton P, Ichikawa I, Inagami T, Schnermann J: Renal physiology of the mouse. Am J Physiol Renal Physiol 2000;278:F339-F351.
24. Dressman JB: Comparison of canine and human gastrointestinal physiology. Pharm Res 1986;3:123-131.
25. Jaeger P, Robertson WG: Role of dietary intake and intestinal absorption of oxalate in calcium stone formation. Nephron Physiol 2004;98:64-71.
26. Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS: Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006;38:474-478.
27. Gelbart DR, Brewer LL, Fajardo LF, Weinstein AB: Oxalosis and chronic renal failure after intestinal bypass. Arch Intern Med 1977;137:239-243.